Skip to main content
Preetesh Jain on Muck Rack

Preetesh Jain

As seen in: Medium, Color Research & Application, Nature, The Lancet, Texas Medical Center, OncLive, Targeted Oncology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Preetesh

Contact Preetesh, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

BRG1-mediated suppression of ferroptosis underlies BTK inhibitor resistance

|
By Soo-Yeon Hwang, Xiangao Huang, Belem Yoval-Sánchez, Peter Martin, Caitlin Gribbin, Preetesh Jain, Michael Wang, Lalit Sehgal, Robert A Baiocchi, Inah Hwang, Alexander Galkin, Hojoong Kwak, Lapo Alinari, Selina Chen-Kiang, Jihye Paik, Helgi Nikolli, Sieun Yang, Jeongbin Heo, Maurizio DiLiberto, Hongwu Zheng
| Nature Verified
Abstract Resistance to Bruton’s tyrosine kinase inhibitors (BTKi) remains a major therapeutic challenge in B-cell malignancies. Here, we identify chromatin remodeler BRG1-mediated suppression of ferroptosis as a central mechanism of BTKi resistance in mantle cell lymphoma (MCL), in which aberrant BRG1-dependent transcription program protects cells from BTKi-induced ferroptosis by restricting reactive oxygen species (ROS) and labile iron.
Open in Who Shared Issue with article?

Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma Original

|
By Karan L. Chohan, Eduardo Edelman Saul, R. Eric Davis, Fredrick Hagemeister, Raphael Steiner, Luis Fayad, Sairah Ahmed, Alma Rodriguez, Swaminathan Iyer, Ranjit Nair, Francisco Vega, Dai Chihara, Preetesh Jain, Luis Castillo, Chijioke Nze, Fateeha Furqan, Ayushi F. Chauhan, Mark Hamilton, Jared Henderson, Anath C. Lionel, Christopher Flowers, Sattva Neelapu, Michael Green, Jason R Westin
| Nature Verified
Diffuse large B-cell lymphoma (DLBCL) represents the most common non-Hodgkin lymphoma, in which ~60–85% of patients achieve a complete response (CR) with standard frontline chemoimmunotherapy approaches [1,2,3]. Despite these promising response rates, ~40% of patients can develop relapsed or refractory disease, and significant research efforts have been devoted to improving the durability and response with frontline therapies through the incorporation of novel agents [1, 2].
Open in Who Shared View Duplicates (2) Issue with article?

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton’s tyrosine kinase inhibitor therapy

|
By Yucai Wang, Melissa Larson, Steven Hwang, Diego Villa, Laveniya Kugathasan, Anita Kumar Verified, Ashlee Joseph, Taylor Brooks, Brian Hill, David Bond, Kami J. Maddocks, Alexey B. Danilov, Jia Ruan, Imran Nizamuddin, Brad S. Kahl, Natalie Grover Verified, Georgios Pongas, Izidore S. Lossos, Evguenia Ouchveridze, Aung M. Tun, Firas Baidoun, Muhamad Alhaj Moustafa, Zoey Harris, Javier Muñoz, Philip Young, Craig Portell, Patrick M Reagan, Christine Ryan, Reid W. Merryman, Arash Velayati, Drew Gerber, Preetesh Jain, Michael Wang, Eric Mou, Lauren G. Banaszak, Priyanka A. Pophali, Anthony Stack, Marcus Messmer, Mayur Narkhede, Amitkumar Mehta, Nilanjan Ghosh, Rahul S Bhansali, Stefan K. Barta, Manali K. Kamdar, Jacob L. Anna, Reem Karmali, Matthew J. Maurer, James R. Cerhan, Jonathon Cohen, Peter Martin, Christine Argao, Nazneen B. Khan, I. Brian Greenwell, Sabarish R. Ayyappan, Tamara K. Moyo, Alexander V. Stanisic
| Nature Verified
Abstract Addition of Bruton’s tyrosine kinase inhibitor (BTKi) to first-line (1 L) bendamustine-rituximab (BR) improved progression-free survival (PFS) in patients with mantle cell lymphoma (MCL) in the SHINE and ECHO trials. We investigated whether sequential treatment with 1 L BR and second-line (2 L) BTKi can result in similar cumulative PFS compared to BR-BTKi combination therapy, using a multicenter cohort of 755 patients treated with 1 L BR between 2014 and 2020.
Open in Who Shared Issue with article?
See all 17 licensed articles (23 Total)